These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18594792)

  • 1. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
    Chen J; Li D; Schaefer R; Mehta JL
    Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
    Chen J; Li D; Schaefer RF; Mehta JL
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Engelhorn T; Doerfler A; Heusch G; Schulz R
    Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
    Krämer S; Kron S; Wang-Rosenke Y; Loof T; Khadzhynov D; Morgera S; Kawachi H; Shimizu F; Martini S; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F801-11. PubMed ID: 18216152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
    Chow BS; Koulis C; Krishnaswamy P; Steckelings UM; Unger T; Cooper ME; Jandeleit-Dahm KA; Allen TJ
    Diabetologia; 2016 Aug; 59(8):1778-90. PubMed ID: 27168137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
    Schäfer K; Kaiser K; Konstantinides S
    Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis.
    Grönros J; Wikström J; Brandt-Eliasson U; Forsberg GB; Behrendt M; Hansson GI; Gan LM
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2046-53. PubMed ID: 18790840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Rizos CV; Liberopoulos EN; Tellis K; DiNicolantonio JJ; Tselepis AD; Elisaf MS
    Angiology; 2015 Jan; 66(1):36-42. PubMed ID: 24288364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin Attenuates Progression of Atherosclerosis and Reduces Serum IL6 and CCL2 Levels in Apolipoprotein-E-deficient Mice.
    Tsilimigras DI; Thanopoulou K; Salagianni M; Siasos G; Oikonomou E; Perrea DD; Nirakis N; Filis K; Tsioufis K; Tousoulis D; Sigala F
    In Vivo; 2023; 37(3):994-1002. PubMed ID: 37103114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment?
    Marzoll A; Melchior-Becker A; Cipollone F; Fischer JW
    J Cell Mol Med; 2011 Feb; 15(2):232-43. PubMed ID: 20015203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin.
    Osaka M; Hagita S; Yoshida M
    Biomed Res Int; 2013; 2013():962369. PubMed ID: 23509822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan.
    Hayashi K; Sasamura H; Azegami T; Itoh H
    J Atheroscler Thromb; 2012; 19(8):736-46. PubMed ID: 22576470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
    Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
    J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
    Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
    J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
    Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
    Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.